An Investigation of the BRCA2 Met1915Thr Polymorphism in Azerbaijani Breast Cancer Patients
Abstract
1. Introduction
2. Materials and Methods
2.1. Subjects
2.2. Genotyping
2.3. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
ORs | Odds Ratios |
CIs | Confidence Intervals |
WHO | World Health Organization |
Met | Methionine |
Thr | Threonine |
EDTA-Na | Ethylenediaminetetraacetic Acid Disodium Salt |
References
- Allahverdiyev, A.; Tari, G.; Bagirova, M.; Abamor, E.S. Current Approaches in Development of Immunotherapeutic Vaccines for Breast Cancer. J. Breast Cancer 2018, 21, 343–353. [Google Scholar] [CrossRef]
- Krupa, R.; Sliwinski, T.; Morawiec, Z.; Pawlowska, E.; Zadrozny, M.; Blasiak, J. Association between polymorphisms of the BRCA2 gene and clinical parameters in breast cancer. Exp. Oncol. 2009, 31, 250–251. [Google Scholar] [PubMed]
- Solodskikh, S.A.; Panevina, A.V.; Gryaznova, M.V.; Gureev, A.P.; Serzhantova, O.V.; Mikhailov, A.A.; Maslov, A.Y.; Popov, V.N. Targeted sequencing to discover germline variants in the BRCA1 and BRCA2 genes in a Russian population and their association with breast cancer risk. Mutat. Res. 2019, 813, 51–57. [Google Scholar] [CrossRef]
- Dinparvar, S.; Bagirova, M.; Allahverdiyev, A.M.; Abamor, E.S.; Safarov, T.; Aydogdu, M.; Aktas, D. A nanotechnology-based new approach in the treatment of breast cancer: Biosynthesized silver nanoparticles using Cuminum cyminum L. seed extract. J. Photochem. Photobiol. B 2020, 208, 111902. [Google Scholar] [CrossRef]
- Bradbury, A.R.; Olopade, O.I. Genetic susceptibility to breast cancer. Rev. Endocr. Metab. Disord. 2007, 8, 255–267. [Google Scholar] [CrossRef]
- Wisniewska-Jarosinska, M.; Sliwinski, T.; Kasznicki, J.; Kaczmarczyk, D.; Krupa, R.; Bloch, K.; Drzewoski, J.; Chojnacki, J.; Blasiak, J.; Morawiec-Sztandera, A. Cytotoxicity and genotoxicity of capecitabine in head and neck cancer and normal cells. Mol. Biol. Rep. 2011, 38, 3679–3688. [Google Scholar] [CrossRef]
- Baynes, C.; Healey, C.S.; Pooley, K.A.; Scollen, S.; Luben, R.N.; Thompson, D.J.; Pharoah, P.D.P.; Easton, D.F.; Ponder, B.A.J.; Dunning, A.M.; et al. Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res. 2007, 9, R27. [Google Scholar] [CrossRef] [PubMed]
- Couch, F.J.; Wang, X.; McGuffog, L.; Lee, A.; Olswold, C.; Kuchenbaecker, K.B.; Soucy, P.; Fredericksen, Z.; Barrowdale, D.; Dennis, J.; et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 2013, 9, e1003212. [Google Scholar] [CrossRef]
- Kazandjian, V.A. Genetic polymorphisms and breast cancer risk. JAMA 1997, 277, 533. [Google Scholar] [CrossRef] [PubMed]
- Osorio, A.; Milne, R.L.; Pita, G.; Peterlongo, P.; Heillinen, T.; Simard, J.; Chenevix-Trench, G.; Spurdle, A.B.; Beesley, J.; Chen, Z.; et al. Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. J. Cancer 2009, 101, 2048–2054. [Google Scholar] [CrossRef]
- Rebbeck, T.R.; Kantoff, P.W.; Krithivas, K.; Neuhausen, S.; Blackwood, M.A.; Godwin, A.K.; Daly, M.B.; Narod, S.A.; Garber, J.E.; Lynch, H.T.; et al. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am. J. Hum. Genet. 1999, 64, 1371–1377. [Google Scholar] [CrossRef] [PubMed]
- Rebbeck, T.R.; Mitra, N.; Wan, F.; Sinilnikova, O.M.; Healey, S.; McGuffog, L.; Mazoyer, S.; Chenevix-Trench, G.; Easton, D.F.; Antoniou, A.C.; et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 2015, 313, 1347–1361. [Google Scholar] [CrossRef]
- Sliwinski, T.; Krupa, R.; Majsterek, I.; Rykala, J.; Kolacinska, A.; Morawiec, Z.; Drzewoski, J.; Zadrozny, M.; Blasiak, J. Polymorphisms of the BRCA2 and RAD51 genes in breast cancer. Breast Cancer Res. Treat. 2005, 94, 105–109. [Google Scholar] [CrossRef]
- Spurdle, A.B.; Couch, F.J.; Parsons, M.T.; McGuffog, L.; Barrowdale, D.; Bolla, M.K.; Wang, Q.; Healey, S.; Schmutzler, R.; Wappenschmidt, B.; et al. Investigators. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: A large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res. 2014, 16, 3419. [Google Scholar] [CrossRef]
- Denisov, E.V.; Cherdyntseva, N.V.; Litviakov, N.V.; Malinovskaya, E.A.; Babyshkina, N.N.; Belyavskaya, V.A.; Voevoda, M.I. Mutations in the TP53 tumor suppressor gene and their association with clinical features of breast cancer. Sib. J. Oncol. 2008, 2, 79–110. [Google Scholar]
- Johnson, N. Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum. Mol. Genet. 2007, 16, 1051–1057. [Google Scholar] [CrossRef] [PubMed]
- Orelli, B.J.; Bishop, D.K. BRCA2 and homologous recombination. Breast Cancer Res. 2001, 3, 294–298. [Google Scholar] [CrossRef]
- Fackenthal, J.D.; Olopade, O.I. Breast Cancer Risk Associated with BRCA1 and BRCA2 in Diverse Populations. Nat. Rev. Cancer 2007, 7, 937–948. [Google Scholar] [CrossRef]
- Górski, B.; Narod, S.A.; Łubiński, J. A Common Missense Variant in BRCA2 Predisposes to Early Onset Breast Cancer. Breast Cancer Res. 2005, 7, R1023–R1027. [Google Scholar] [CrossRef] [PubMed]
- Shanazarov, N.; Zhapparov, Y.; Kumisbekova, R.; Turzhanova, D.; Zulkhash, N. Association of Gene Polymorphisms with Breast Cancer Risk in the Kazakh Population. Asian Pac. J. Cancer Prev. 2023, 24, 4195–4207. [Google Scholar] [CrossRef]
- Svyatova, G.; Berezina, G.; Urazbayeva, G.; Murtazaliyeva, A. Frequencies of Diagnostically Significant Polymorphisms of Hereditary Breast Cancer Forms in BRCA1 and BRCA2 Genes in the Kazakh Population. Asian Pac. J. Cancer Prev. 2023, 24, 3899. [Google Scholar] [CrossRef]
- Faramarzi, S.; Dianatpour, A.; Ghafouri-Fard, S. Association of BRCA2 variants with breast cancer risk: A meta-analysis. Meta Gene 2018, 17, 9–16. [Google Scholar] [CrossRef]
- Jan, H.; Khan, N.U.; Al-Qaaneh, A.M.; Tasleem, M.; Almutairi, M.H.; Ali, I. BRCA2 Polymorphisms and Breast Cancer Susceptibility: A Multi-Tools Bioinformatics Approach. Cell Physiol. Biochem. 2024, 58, 128–143. [Google Scholar] [PubMed]
- Lilyquist, J.; Ruddy, K.J.; Vachon, C.M.; Couch, F.J. Common Genetic Variation and Breast Cancer Risk: Past, Present, and Future. Cancer Epidemiol. Biomark. Prev. 2018, 27, 380–394. [Google Scholar] [CrossRef] [PubMed]
- Serrano-Fernández, P.; Debniak, T.; Górski, B.; Bogdanova, N.; Dörk, T.; Cybulski, C.; Huzarski, T.; Byrski, T.; Gronwald, J.; Wokołorczyk, D.; et al. Synergistic Interaction of Variants in CHEK2 and BRCA2 on Breast Cancer Risk. Breast Cancer Res. Treat. 2009, 117, 161–165. [Google Scholar] [CrossRef]
- Dombernowsky, S.L.; Weischer, M.; Freiberg, J.J.; Bojesen, S.E.; Tybjærg-Hansen, A.; Nordestgaard, B.G. Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer. Cancer Epidemiol. Biomark. Prev. 2009, 18, 2339–2342. [Google Scholar] [CrossRef]
Patients N = 144 (%) | Controls N = 152 (%) | p Value | |
---|---|---|---|
Age | 0.259 | ||
Age interval | 35–81 | 42–89 | |
Mean | 58 ± 5 | 59 ± 5 | |
Grade | |||
I | 26 (18.1) | ||
II | 103 (71.5) | ||
III | 15 (10.4) | ||
TNM staging | |||
I | 14 (9.7) | ||
II | 59 (41) | ||
III | 8 (5.7) | ||
IV | 63 (43.6) |
Genotype | Patients N = 144 (%) | Controls N = 152 (%) | OR (95%CI) | p Value |
---|---|---|---|---|
Met/Met | 58 (40.3) | 84 (55.3) | 1 | - |
Met/Thr | 52 (36.1) | 41 (27) | 1.83 (1.08–3.11) | 0.02 |
Thr/Thr | 34 (23.6) | 27 (17.7) | 1.82 (0.99–3.34) | 0.05 |
Dominant Model | ||||
Met/Met | 58 (40.3) | 84 (55.3) | 1 | - |
Met/Thr + Thr/Thr | 86 (59.7) | 68 (44.7) | 1.83 (1.15–2.90) | 0.01 |
Recessive Model | ||||
Met/Met + Met/Thr | 110 (76.4) | 125 (82.3) | 1 | - |
Thr/Thr | 34 (23.6) | 27 (17.7) | 1.43 (0.81–2.52) | 0.21 |
Allele | ||||
Met | 168 (58.3) | 209 (68.8) | 1 | - |
Thr | 120 (41.7) | 95 (31.2) | 1.57 (1.12–2.20) | 0.008 |
Age ≤ 58 | Patients, N = 69 (%) | Controls, N = 51 (%) | OR (95%CI) | p Value |
---|---|---|---|---|
Met/Met | 32 (46.4) | 29 (56.9) | 1 | - |
Met/Thr | 22 (31.9) | 14 (27.5) | 1.42 (0.61–3.29) | 0.41 |
Thr/Thr | 15 (21.7) | 8 (15.6) | 1.69 (0.62–4.59) | 0.29 |
Age > 58 | Patients, N = 75 (%) | Controls, N = 101 (%) | ||
Met/Met | 26 (34.7) | 55 (54.5) | 1 | - |
Met/Thr | 30 (40) | 27 (26.7) | 2.35 (1.17–4.73) | 0.02 |
Thr/Thr | 19 (25.3) | 19 (18.8) | 2.11 (0.96–4.65) | 0.06 |
Met/Met N (%) | Met/Thr N (%) | Thr/Thr N (%) | p Value | |
---|---|---|---|---|
Tumor grade | 0.48 | |||
G1 | 10 (38.5) | 13 (50) | 3 (11.5) | |
G2 | 42 (40.8) | 33 (32) | 28 (27.2) | |
G3 | 6 (40) | 6 (40) | 3 (20) | |
Tumor stage | 0.88 | |||
T1 | 6 (42.9) | 5 (35.7) | 3 (21.4) | |
T2 | 25 (42.4) | 21 (35.6) | 13 (22) | |
T3 | 3 (37.5) | 2 (25) | 3 (37.5) | |
T4 | 24 (38.1) | 24 (38.1) | 15 (23.8) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Safarzade, Z.; Bayramov, B.; Mehdiyeva, N.; Valiyeva, H.; Ahmadova, G.; Kerimova, R.; Qurbanova, Q.; Isayev, O.; Allahverdiyev, A. An Investigation of the BRCA2 Met1915Thr Polymorphism in Azerbaijani Breast Cancer Patients. Med. Sci. 2025, 13, 103. https://doi.org/10.3390/medsci13030103
Safarzade Z, Bayramov B, Mehdiyeva N, Valiyeva H, Ahmadova G, Kerimova R, Qurbanova Q, Isayev O, Allahverdiyev A. An Investigation of the BRCA2 Met1915Thr Polymorphism in Azerbaijani Breast Cancer Patients. Medical Sciences. 2025; 13(3):103. https://doi.org/10.3390/medsci13030103
Chicago/Turabian StyleSafarzade, Zumrud, Bayram Bayramov, Nigar Mehdiyeva, Hagigat Valiyeva, Gunay Ahmadova, Rena Kerimova, Qamar Qurbanova, Orkhan Isayev, and Adil Allahverdiyev. 2025. "An Investigation of the BRCA2 Met1915Thr Polymorphism in Azerbaijani Breast Cancer Patients" Medical Sciences 13, no. 3: 103. https://doi.org/10.3390/medsci13030103
APA StyleSafarzade, Z., Bayramov, B., Mehdiyeva, N., Valiyeva, H., Ahmadova, G., Kerimova, R., Qurbanova, Q., Isayev, O., & Allahverdiyev, A. (2025). An Investigation of the BRCA2 Met1915Thr Polymorphism in Azerbaijani Breast Cancer Patients. Medical Sciences, 13(3), 103. https://doi.org/10.3390/medsci13030103